Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-116 plus Palbociclib in Advanced Breast Cancer and Solid Tumors
NCT05655598Phase 1Withdrawn
- Sponsor
- Brown University
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pimitespib in breast cancer and solid tumor (3 arms), sponsored by Brown University. Primary endpoint: Safety and tolerability of TAS-116 with palbociclib. Planned start Sep 2023; status: withdrawn.
02
Drugs
pimitespib
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05655598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655598.